Supplementary Figures 1-4; Supplementary Tables 1 & 2 from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide

Authors:
  • AGAmy D. Guertin
    Amy D. Guertin
  • JOJennifer O'Neil
    Jennifer O'Neil
  • ASAlexander Stoeck
    Alexander Stoeck
  • JRJoseph A. Reddy
    Joseph A. Reddy
  • RCRazvan Cristescu
    Razvan Cristescu
  • BHBrian B. Haines
    Brian B. Haines
  • MHMarlene C. Hinton
    Marlene C. Hinton
  • RDRyan Dorton
    Ryan Dorton
  • ABAlicia Bloomfield
    Alicia Bloomfield
  • MNMelissa Nelson
    Melissa Nelson
  • MVMarilynn Vetzel
    Marilynn Vetzel
  • SLSerguei Lejnine
    Serguei Lejnine
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure 1: Assessment of kidney cancer cell lines A498, 786-O, and A704 via flow cytometry revealed surface expression of P-gp in all lines; Supplementary Figure 2: 786-O and A704 cells were transduced with lentiviral FR1, and flow cytometric analysis shows increased surface FR1 expression; Supplementary Figure 3: NCI/ADR-RES or NCI/ADR-RES-FR cells with known FR levels were treated with increasing concentrations (10-9 M to 10-5 M) of vintafolide for 2 h; Supplementary Figure 4: Ovarian tumors positive for P-gp tend to express lower levels of FR; Supplementary Table 1: P-gp inhibitor elacridar reverses P-gp-mediated DAVLBH and vintafolide resistance; Supplementary Table 2: Functional multi-drug transporter efflux assay.